

REQUEST FOR PROPOSAL: ACCELERATING DRUG DISCOVERY FOR FRONTOTEMPORAL DEGENERATION

UPCOMING DEADLINES

Must be received by 5:00 pm ET on the deadline date.

Letter of Intent

July 13, 2018

Invited Full Proposal

August 10, 2018

Average Duration

One year with potential for follow-on funding.

Average Award

\$100,000-\$150,000

Eligibility

Funding is open to researchers and clinicians in the U.S. and worldwide working in:

- **Academic** medical centers and universities or nonprofits. Industry partnerships are strongly encouraged.
- **Biotechnology companies** that demonstrate a clear need for nonprofit funding. Funding is provided through mission-related investments (MRIs) that require return on investment based upon scientific and/or business milestones. Existing companies and new spinouts are both eligible.

INTRODUCTION

Research investigating the pathogenic mechanisms underlying frontotemporal degeneration (FTD) is advancing, creating new



targets for drug discovery. However, there remains a global gap in FTD drug discovery research. The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug discovery programs for FTD through this request for proposals (RFP).

FUNDING PRIORITIES

- Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and *in vitro* ADME.
- Testing of novel lead compounds, biologics, or repurposed drug candidates in relevant animal models for *in vivo* pharmacokinetics, dose-range finding, target engagement, *in vivo* efficacy, and/or preliminary rodent tolerability studies.

For *in vivo* efficacy studies proposals should:

- Demonstrate blood-brain barrier penetration (if the intended target is in the CNS)
- Justify dosing administration and regimen with *in vivo* PK/PD data
- Include measures of target engagement

For studies testing repurposed drugs, proposals should:

- Evaluate known side effects of the drug and how well they would be tolerated by the intended FTD patients.
- Identify a supplier that will provide sufficient quantities of the drug or compound to complete the study aims.

- Demonstrate plans to develop novel intellectual property around the repurposing/repositioning strategy.
-

This RFP does NOT support target identification, target validation, assay development, or high-throughput and high-content screening.

APPLICATION SUBMISSIONS

Review the Application Instructions for steps on applying.

ADDF FUNDING PORTAL

LOG IN OR CREATE ACCOUNT

For program-related inquiries, please contact:

Lauren Friedman, PhD, Director, Scientific Affairs

Phone: 212.901.8017

E-mail: lfriedman@alzdiscovery.org

Nadine Tatton, PhD, Director, Scientific Director, AFTD

Phone: 267.514.7221

E-mail: ntatton@theaftd.org

For application submission inquiries, please contact:

Grants and Mission-Related Investments Team

Phone: 212.901.7998

E-mail: grants@alzdiscovery.org

Register for the ADDF's Conference on Alzheimer's Drug Discovery

September 17–18, 2018

Join us for the 19th International Conference on Alzheimer's Drug Discovery in Jersey City. This annual conference brings together academic and industry scientists to learn about current research progress from leaders in the field, including the ADDF's funded investigators. [Get more information](#) on scholarships and early bird registration rates.



Alzheimer's Drug Discovery Foundation

*A GuideStar-
Rated Charity*

57 West 57th Street, Suite 904
New York, NY 10019
info@alzdiscovery.org
212.901.8000

© Copyright 2018

Donate**Contact Us****2016 Financials****Careers****Site Map**

[Terms & Conditions](#)

[Privacy Policy](#)